Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;6(9):e1825.
doi: 10.1371/journal.pntd.0001825. Epub 2012 Sep 13.

Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal

Mamadou O Traore  1 , Moussa D Sarr, Alioune Badji, Yiriba Bissan, Lamine Diawara, Konimba Doumbia, Soula F Goita, Lassana Konate, Kalifa Mounkoro, Amadou F Seck, Laurent Toe, Seyni Toure, Jan H F Remme
Affiliations

Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal

Mamadou O Traore et al. PLoS Negl Trop Dis. 2012.

Abstract

Background: Mass treatment with ivermectin controls onchocerciasis as a public health problem, but it was not known if it could also interrupt transmission and eliminate the parasite in endemic foci in Africa where vectors are highly efficient. A longitudinal study was undertaken in three hyperendemic foci in Mali and Senegal with 15 to 17 years of annual or six-monthly ivermectin treatment in order to assess residual levels of infection and transmission, and test whether treatment could be safely stopped. This article reports the results of the final evaluations up to 5 years after the last treatment.

Methodology/principal findings: Skin snip surveys were undertaken in 131 villages where 29,753 people were examined and 492,600 blackflies were analyzed for the presence of Onchocerca volvulus larva using a specific DNA probe. There was a declining trend in infection and transmission levels after the last treatment. In two sites the prevalence of microfilaria and vector infectivity rate were zero 3 to 4 years after the last treatment. In the third site, where infection levels were comparatively high before stopping treatment, there was also a consistent decline in infection and transmission to very low levels 3 to 5 years after stopping treatment. All infection and transmission indicators were below postulated thresholds for elimination.

Conclusion/significance: The study has established the proof of principle that onchocerciasis elimination with ivermectin treatment is feasible in at least some endemic foci in Africa. The study results have been instrumental for the current evolution from onchocerciasis control to elimination in Africa.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Location of the three study foci in Mali and Senegal.
Figure 2
Figure 2. Study design.
Figure 3
Figure 3. Modified study design for the R. Faleme focus.
Figure 4
Figure 4. Location of the fly catching points in the three study sites.
Figure 5
Figure 5. Prevalence of onchocerciasis infection in the R. Bakoye focus before the start of treatment and 1.75–4 years after the last treatment round.
Figure 6
Figure 6. Prevalence of onchocerciasis infection in the R. Gambia focus before the start of treatment and 1.75 to 4 years after the last treatment round.
Figure 7
Figure 7. Prevalence of onchocerciasis infection in the R. Faleme focus before the start of treatment and 1.6 to 5 years after the last treatment round.
See this image and copyright information in PMC

References

    1. Eberhard M, Remme JHF, Richard F (2008) Onchocerciasis. In: Heymann DL, editor. Control of Communicable Diseases Manual. 19 ed. Washington: American Public Health Association. pp. 443–446.
    1. Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, et al. (1993) Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis [see comments]. Lancet 341: 130–134. - PubMed
    1. Cousens SN, Cassels-Brown A, Murdoch I, Babalola OE, Jatau D, et al. (1997) Impact of annual dosing with ivermectin on progression of onchocercal visual field loss. Bull World Health Organ 75: 229–236. - PMC - PubMed
    1. Brieger WR, Awedoba AK, Eneanya CI, Hagan M, Ogbuagu KF, et al. (1998) The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health 3: 951–961. - PubMed
    1. Thylefors B (2008) The Mectizan Donation Program (MDP). Ann Trop Med Parasitol 102 Suppl 139–44. - PubMed

Publication types

MeSH terms